UBX3 Antibody

What is USP3 and how does it function in cellular processes?

USP3 is a deubiquitinase enzyme that plays critical roles in multiple cellular processes including transcriptional regulation, cell cycle progression, and innate immunity. Functionally, USP3 deubiquitinates monoubiquitinated target proteins like histones H2A and H2AX, counteracting ubiquitination mediated by RNF168 and RNF8. This activity is essential for the recruitment of DNA damage repair factors to DNA break sites .

USP3 is also required for proper S phase progression and subsequent mitotic entry. Additionally, it serves as a positive regulator of TP53 by deubiquitinating and stabilizing it, which promotes normal cell proliferation and transformation .

In immune contexts, USP3 participates in establishing tolerance in innate immune memory through non-transcriptional feedback mechanisms. It negatively regulates TLR-induced NF-κB signaling by targeting and removing 'Lys-63'-linked polyubiquitin chains on MYD88, and similarly regulates type I interferon signaling by mediating 'Lys-63'-linked polyubiquitin chains on RIGI and IFIH1 .

What is UBXN3B and how does it relate to immune function?

UBXN3B belongs to the ubiquitin regulatory X (UBX) domain-containing protein family, which functions as putative adaptors for ubiquitin ligases and valosin-containing protein. UBXN3B plays an essential role in B lymphopoiesis, maintaining constitutive pre-BCR signaling and cell survival in a cell-intrinsic manner .

Research has demonstrated that UBXN3B is crucial for activating innate immunity to DNA viruses and controlling DNA/RNA virus infection. Furthermore, both global and B cell-specific UBXN3B knockout mice exhibit marked reduction in small precursor B-II (>60%), immature (>70%), and mature B (>95%) cell numbers .

Mechanistically, UBXN3B deficiency leads to impaired pre-BCR signaling and cell cycle arrest. UBXN3B knockout mice show vulnerability to respiratory viruses, with increased viral loads, prolonged immunopathology in the lung, and reduced production of virus-specific IgM/IgG, highlighting its importance in adaptive immunity .

What applications are suitable for USP3 antibodies in research?

USP3 antibodies are versatile tools for investigating deubiquitination processes in multiple research contexts. Based on available information, USP3 antibodies are suitable for these applications:

• Western Blotting (WB): For detecting USP3 protein expression levels and post-translational modifications in cell lysates.

• Immunocytochemistry/Immunofluorescence (ICC/IF): For visualizing USP3 localization within cells, particularly in response to DNA damage or during cell cycle progression .

For human samples specifically, available rabbit polyclonal USP3 antibodies have been validated for these applications and cited in peer-reviewed publications, confirming their reliability for research use .

How do researchers validate the specificity of UBX-related antibodies?

Validating antibody specificity is crucial for research integrity. For UBX-related antibodies like those targeting USP3 or UBXN3B, researchers typically employ multiple approaches:

• Immunogen verification: Confirming that antibodies are raised against verified recombinant fragments of the target protein. For instance, available USP3 antibodies are generated using recombinant fragment proteins within the human USP3 sequence .

• Application-specific validation: Testing in multiple applications (WB, ICC/IF) with appropriate positive and negative controls.

• Species reactivity testing: Confirming species cross-reactivity through controlled experiments, as species specificity influences experimental design.

• Knockout/knockdown controls: Using knockout or knockdown models to confirm signal specificity, as demonstrated in studies with tamoxifen-inducible global and constitutive B cell-specific UBXN3B knockout mice .

How can researchers utilize antibodies to investigate USP3's role in DNA damage responses?

To effectively study USP3's role in DNA damage responses, researchers should consider these methodological approaches:

• Spatiotemporal analysis of USP3 recruitment: Using immunofluorescence with USP3 antibodies to track protein localization to DNA damage sites over time. This should be combined with markers for DNA damage (γH2AX) and repair factors.

• Ubiquitination dynamics assessment: Employing co-immunoprecipitation with USP3 antibodies followed by ubiquitin western blotting to analyze USP3's impact on the ubiquitination status of histones H2A and H2AX after DNA damage induction.

• ChIP-seq experiments: Using USP3 antibodies for chromatin immunoprecipitation followed by sequencing to map USP3 binding sites across the genome in response to genotoxic stress.

• Functional assays in USP3-depleted cells: Complementing antibody-based detection with functional assays in USP3-knockout or knockdown cells, then restoring expression with WT or catalytically inactive USP3 to determine how deubiquitinase activity affects DNA damage repair factor recruitment .

What strategies are effective for using antibodies to study UBXN3B's impact on B cell development?

When investigating UBXN3B's role in B lymphopoiesis, researchers should implement these methodological approaches:

• Flow cytometric analysis of B cell subpopulations: Using UBXN3B antibodies in conjunction with B cell markers to track developmental stages affected by UBXN3B deficiency.

• Bone marrow transfer experiments: Combining antibody detection with bone marrow transplantation between wild-type and UBXN3B knockout mice to determine cell-intrinsic effects, as demonstrated in research showing that transfer of wild-type bone marrow to irradiated global UBXN3B knockouts restores normal B lymphopoiesis .

• Pre-BCR signaling analysis: Using phospho-specific antibodies to examine pre-BCR signaling components in UBXN3B-deficient B cells, since UBXN3B deficiency leads to impaired pre-BCR signaling.

• Apoptosis assessment: Combining UBXN3B antibody staining with apoptosis markers (Annexin V, cleaved caspase-3) to evaluate the relationship between UBXN3B expression and B cell survival. Research has shown higher pro and activated caspase-3 protein levels following UBXN3B knockout induction .

How can researchers develop and validate AbTACs incorporating UBX-related targeting strategies?

Antibody-based PROTACs (AbTACs) represent an innovative approach for targeted protein degradation. To develop AbTACs potentially incorporating UBX-related targeting strategies, researchers should:

• Select appropriate E3 ligase-binding domains: For membrane protein targets, identify suitable membrane-bound E3 ligases like RNF43, which contains a structured ectodomain facilitating antibody generation and an intracellular RING domain for ubiquitination .

• Generate high-affinity recombinant antibodies: Utilize phage display to develop antibodies against both the target protein and the selected E3 ligase, ensuring affinities in the nanomolar range. For example, researchers have generated Fabs with KD values of 12.5 nM for RNF43 .

• Construct bispecific antibodies: Employ validated approaches like knobs-into-holes Fc constructs to ensure correct heavy chain pairing, followed by in vitro assembly to construct functional bispecific antibodies .

• Validate dual binding capacity: Confirm that the bispecific antibody can simultaneously bind both the target protein and E3 ligase using techniques like biolayer interferometry (BLI) .

• Assess degradation efficiency: Measure target protein reduction over time to determine parameters like maximum degradation percentage (DMax) and degradation half-life (DC50) .

What methodological challenges exist when using antibodies to investigate UBX-related proteins in viral immunity?

Investigating UBX-related proteins in viral immunity presents several methodological challenges that researchers must address:

• Temporal dynamics: UBXN3B activation occurs rapidly after viral infection, requiring precise timing for sample collection and antibody-based detection. Researchers should establish detailed time-course experiments.

• Cell-type heterogeneity: Since UBXN3B functions differ between innate immune cells and B cells, researchers must carefully isolate specific cell populations before antibody-based analysis to avoid misinterpreting mixed cell population data.

• Cross-talk between pathways: UBXN3B influences both cGAS-STING signaling and B cell receptor signaling . When using antibodies to study these pathways, researchers must design experiments that can distinguish direct UBXN3B effects from secondary consequences.

• Appropriate viral models: As shown in studies using SARS-CoV-2 and influenza in tamoxifen-inducible global and constitutive B cell-specific UBXN3B knockout mice , selecting appropriate viral models is crucial for relevant findings.

• Integration with functional readouts: Antibody-based detection should be complemented with functional assays measuring viral loads and virus-specific antibody production to establish meaningful correlations between UBXN3B expression and antiviral immunity.

How can researchers leverage antibodies to explore the therapeutic potential of targeting USP3 or UBXN3B?

To investigate the therapeutic potential of targeting USP3 or UBXN3B, researchers can employ antibodies in these strategic approaches:

• Target validation in disease models: Use antibodies to correlate USP3/UBXN3B expression with disease progression in relevant models. For UBXN3B, its essential role in B lymphopoiesis suggests potential therapeutic targets for B-cell related diseases such as B lymphomas and autoimmunity .

• Mechanism of action studies: Employ antibodies to elucidate how USP3/UBXN3B influences disease-relevant pathways. For USP3, investigate its role in TP53 stabilization for cancer applications, or its regulation of inflammasome activation through ASC/PYCARD deubiquitination for inflammatory conditions .

• Therapeutic antibody development: For extracellular domains of UBXN proteins, develop blocking antibodies that could modulate function without requiring cell entry.

• AbTAC therapeutic potential: Explore the application of antibody-based PROTACs (AbTACs) for targeting disease-relevant proteins by recruiting E3 ligases, leveraging the modular nature and genetic tractability of AbTACs which offer promise for translational applications .

• Biomarker identification: Use validated antibodies to determine if USP3/UBXN3B expression levels could serve as biomarkers for disease progression or treatment response, particularly in the context of viral infections or immune disorders.

What are the most common technical issues when using USP3 or UBXN3B antibodies?

When working with USP3 or UBXN3B antibodies, researchers frequently encounter these technical challenges:

• Background signal in Western blotting: Optimize blocking conditions (try different blocking agents like BSA or milk proteins) and antibody dilutions. For USP3 detection, starting with manufacturer-recommended dilutions for the specific antibody is advised .

• Subcellular localization variability: USP3 can shift localization in response to DNA damage, potentially confounding immunofluorescence results. Include appropriate time-course experiments with DNA damage-inducing agents to account for this dynamic behavior.

• Variable detection in primary cells: Primary isolated B cells may show different expression levels of UBXN3B compared to cell lines. Adjust antibody concentrations accordingly and include positive controls from tissues known to express the target.

• Cross-reactivity concerns: Validate antibody specificity using knockout controls, particularly important for UBXN3B studies where the protein has high sequence conservation (98% identity) between humans and rodents .

• Epitope masking: Post-translational modifications or protein interactions may mask antibody epitopes. Consider using multiple antibodies recognizing different epitopes, particularly when studying USP3's interactions with ubiquitinated substrates.

How should researchers design experiments to distinguish between functions of closely related UBX family members?

To effectively differentiate between functions of related UBX family members:

• Employ isoform-specific antibodies: Carefully select antibodies raised against unique regions of each UBX family member. Validate specificity using overexpression systems with tagged versions of each family member.

• Implement genetic approaches: Use CRISPR/Cas9 to generate specific knockouts of individual UBX family members, then use validated antibodies to confirm complete protein elimination.

• Conduct rescue experiments: In knockout models, perform rescue experiments with wild-type and mutant versions of the specific UBX family member to confirm phenotype specificity.

• Utilize domain-specific analysis: For UBXN3B specifically, its functions in maintaining pre-BCR signaling and promoting B cell survival appear independent of the cGAS-STING signaling pathway . Design experiments that can separate these distinct functional pathways.

• Apply interactome profiling: Use immunoprecipitation with specific antibodies followed by mass spectrometry to identify unique binding partners for each UBX family member, helping to distinguish their functional networks.

How is antibody technology advancing the study of UBX proteins in immune regulation?

Advanced antibody technologies are expanding our understanding of UBX proteins in immune regulation through several innovative approaches:

• Single-cell antibody-based profiling: Integration of UBXN3B antibodies with single-cell RNA sequencing has revealed heterogeneity in UBXN3B expression across immune cell subsets, enabling more precise characterization of its role in different immune populations .

• Proximity-based labeling: New antibody-guided proximity labeling techniques (BioID, APEX) allow researchers to map the dynamic interactome of USP3 and UBXN3B in different immune contexts, revealing previously unknown regulatory partners.

• Intrabody development: Engineering antibody fragments that function inside cells (intrabodies) to block specific protein-protein interactions of UBX family members without eliminating the entire protein.

• AbTAC innovation: The development of antibody-based PROTACs represents a significant advancement, offering fully recombinant bispecific antibodies that can recruit membrane-bound E3 ligases for targeted protein degradation .

• In vivo imaging: Using fluorescently-labeled antibodies against UBX family members for in vivo imaging in animal models during immune responses, providing spatial and temporal resolution of protein dynamics during infection.

What role might USP3 or UBXN3B antibodies play in COVID-19 and other viral infection research?

USP3 and UBXN3B antibodies offer valuable tools for advancing COVID-19 and broader viral infection research:

• Infection susceptibility mechanistic studies: UBXN3B knockout mice show increased vulnerability to respiratory viruses, including higher viral loads and prolonged immunopathology in the lung . Antibodies can help track UBXN3B expression changes during infection progression.

• Adaptive immunity investigation: Research shows UBXN3B is essential for producing virus-specific IgM/IgG antibodies. Anti-UBXN3B antibodies can help monitor how this protein regulates B cell responses during viral infections .

• Therapeutic target identification: Both USP3 and UBXN3B influence innate immune pathways. USP3 regulates NF-κB signaling by removing 'Lys-63'-linked polyubiquitin chains on MYD88, while UBXN3B activates innate immunity to DNA viruses . Antibodies can help validate these as potential therapeutic targets.

• Inflammasome regulation assessment: USP3 deubiquitinates ASC/PYCARD, promoting inflammasome activation . Using USP3 antibodies can help understand how this process contributes to the hyperinflammation seen in severe COVID-19.

• Cross-viral immunity comparisons: With rising concerns about pandemic potential, antibodies against USP3 and UBXN3B can help compare their roles across multiple respiratory viruses beyond SARS-CoV-2, including influenza, as demonstrated in existing research .

How can researchers most effectively combine multiple antibody detection methods to gain comprehensive insights into UBX protein functions?

To achieve comprehensive understanding of UBX protein functions, researchers should implement multi-modal antibody-based approaches:

• Integrated omics strategy: Combine antibody-based proteomics (immunoprecipitation-mass spectrometry) with transcriptomics (RNA-seq) and epigenomics (ChIP-seq) to correlate UBX protein levels with gene expression changes and chromatin states.

• Multi-parameter flow cytometry: Utilize multiple antibodies to simultaneously detect UBX proteins and phosphorylation states of signaling molecules in the same cells, providing single-cell resolution of signaling events. This approach has been valuable in studying UBXN3B's effects on B cell development stages .

• Live-cell imaging with functional readouts: Combine fluorescently-tagged antibody fragments with activity-based sensors to correlate UBX protein localization with real-time functional changes in cells.

• Tissue-level to molecular-level analysis: Start with immunohistochemistry to identify tissue distribution patterns, follow with flow cytometry for cell-type specific expression, then employ super-resolution microscopy for subcellular localization, and finally use proximity ligation assays to detect specific protein-protein interactions.

• Validation across model systems: Apply consistent antibody-based detection methods across multiple model systems (cell lines, primary cells, animal models) to distinguish conserved versus context-specific functions of UBX proteins.